Loading...

LYEL LYELL IMMUNOPHARMA INC US FDA Inspections 8-K Filing

LYLL

LYL

LYELL IMMUNOPHARMA INC

(LYEL)

2025 8-K

Show Summary

Show Summary

Merger of Equals

New Clinical Data

Financial Statements

Facility Closure

Financial Results

Acquisition Completed

Clinical Data Release

Board Resignation

Financial Results

Merger Completion

Merger Agreement

Earnings Report

Phase 1 Trial Data Announce...

Earnings Report

Earnings Reports

Repricing of Underwater Opt...

Financial Results Announcement

Investor Presentation

Earnings Report

Annual Meeting of Stockholders

Resignation of Chief Legal ...

Earnings Report

Earnings Reports

External Links:

On June 17, 2025, Lyell Immunopharma, Inc. announced encouraging clinical data from its LYL314 trial for treating large B-cell lymphoma, showing an 88% overall response rate and 72% achieving complete response in heavily treated patients. The company expects to start a pivotal trial for LYL314 in early 2026, with plans to manufacture over 1,200 doses at their facility.

AI Assistant

LYELL IMMUNOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.